Pricing Log in Create free account

Keros Therapeutics, Inc. (KROS) vs Q32 Bio Inc. (QTTB)

Keros Therapeutics, Inc. and Q32 Bio Inc. are both Biotechnology companies. Keros Therapeutics, Inc. and Q32 Bio Inc. are of similar size ($231.3M and $220.1M). Keros Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Q32 Bio Inc. trades at 2.5×. Keros Therapeutics, Inc. grew revenue faster over the last twelve months: −84.6% against −307.3%. Across the 12 metrics below, Q32 Bio Inc. leads on 8 and Keros Therapeutics, Inc. on 4.

Valuation

Metric KROS QTTB Biotechnology median
P/E n/m 2.49 8.50
P/S 6.37 n/m 9.71
P/B 0.81 1.44 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.46 n/m 0.64
EV/Sales (1.39) (8.25) 9.21
Earnings yield (34.64%) 40.16% (33.15%)
Free cash flow yield (22.93%) (8.43%) (25.50%)

Profitability

Metric KROS QTTB Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (17.16%) 72.14% (56.36%)
Return on assets (15.92%) 37.13% (48.04%)
Return on invested capital (1,345.30%) 0.00% 0.00%

Growth

Metric KROS QTTB Biotechnology median
Revenue growth (TTM) (84.55%) (307.33%) 6.02%
EPS growth (last fiscal year) 146.00% 148.96% 30.26%
Revenue growth, 5-year CAGR 89.45% 100.32% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KROS QTTB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 21.96 20.30 4.72
Net debt to EBITDA (4.16) (2.21) 0.96

Dividend

Metric KROS QTTB Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric KROS QTTB Biotechnology median
Market cap 220.08m 231.31m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack